IP Library Granted Patent US 11,536,717
Granted Patent B2
US 11,536,717 · App. 16/256,732 · Granted Dec 27, 2022

Method of agglutination immunoassay

Inventors: Hiroshi Takahashi (Tokyo, JP); Tadaaki Yoshida (Tokyo, JP); Yoshimasa Banba (Tokyo, JP); Yuki Takahashi (Tokyo, JP)
Assignee: HITACHI HIGH-TECH CORPORATION
G01N33/54313G01N21/31G01N21/47G01N21/59G01N21/83G01N2021/1734G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,536,717
App. No.
16/256,732
Granted
Dec 27, 2022
Kind
B2
Abstract

The present invention provides a particle enhanced agglutination immunoassay including the steps of: mixing a sample solution containing an analyte with a solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte to prepare a mixed solution; determining a variation (i) in intensity of light scattered from the mixed solution based on a difference in intensity of scattered light between first and second time points; determining a variation (ii) in absorbance of the mixed solution based on a difference in absorbance between third and fourth time points; and correlating the determined variation (i) in intensity of scattered light and the determined variation (ii) in absorbance with an amount of the analyte present in the sample using a calibration curve plotted based on the variation in intensity of scattered light and a calibration curve plotted based on the variation in absorbance. The present invention employs measurements of the intensity of scattered light and the absorbance in combination for a single assay, and thus provides a particle enhanced agglutination immunoassay which achieves higher sensitivity and a wider dynamic range than conventional assays.

Claims (13)

1. A particle enhanced agglutination immunoassay comprising the steps of:

mixing a sample solution containing an analyte with a solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte to prepare a mixed solution;

determining a variation (i) in intensity of light scattered from the mixed solution based on a difference in intensity of scattered light between a first and a second time point;

determining a variation (ii) in absorbance of the mixed solution based on a difference in absorbance between a third and a fourth time point; and

correlating the determined variation (i) in intensity of scattered light and the determined variation (ii) in absorbance with an amount of the analyte present in the sample using a calibration curve plotted based on the variation in intensity of scattered light and a calibration curve plotted based on the variation in absorbance,

wherein at a low concentration of analyte, the concentration is determined based on the calibration curve plotted based on the measurement of the intensity of scattered light and at a high concentration of analyte, the concentration is determined based on the calibration curve plotted based on the measurement of the absorbance; and

wherein the time period which is defined by the third and fourth time points and for which the variation (ii) is determined is shorter than the time period which is defined by the first and second time points and for which the variation (i) is determined, and the determining a variation (i) in intensity light scattered and the determining a variation (ii) in absorbance are combined in a single assay.

2. The immunoassay according to claim 1 , wherein the first, second, third, and fourth time points are respectively selected between 0 and 1000 seconds after the start of preparation of the mixed solution.

3. The immunoassay according to claim 1 , wherein the variations (i) and (ii) are determined at the same wavelength.

4. The immunoassay according to claim 1 , wherein the variation (ii) in absorbance is determined at a wavelength within a range of ±25% of a wavelength at which the variation (i) in intensity of scattered light is determined.

5. The immunoassay according to claim 4 , wherein the variation (ii) in absorbance is determined at two wavelengths consisting of main and sub-wavelengths which are shorter and longer, respectively, than the wavelength at which the variation (i) in intensity of scattered light is determined.

6. The immunoassay according to claim 1 , wherein the variations (i) and (ii) are determined at a wavelength within the range of from 550 to 900 nm.

7. The immunoassay according to claim 1 , wherein said calibration curves cover at least a range consisting of said low concentration of analyte and said high concentration of analyte.

Assignments (2)
CHANGE OF NAME Recorded Jul 9, 2020
From: HITACHI HIGH-TECHNOLOGIES CORPORATION
To: HITACHI HIGH-TECH CORPORATION
Reel/Frame 053169/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2020
From: SEKISUI MEDICAL CO., LTD.
To: SEKISUI MEDICAL CO., LTD.; HITACHI HIGH-TECHNOLOGIES CORPORATION
Reel/Frame 051670/0501 →
Priority Claims (1)
JP 2013-115756 · May 31, 2013 · national
Continuity (2)
Continuation 14894207
Related Publication 20190154674A1 · May 23, 2019